Epigral Limited announces a new order win

Executive Summary

Epigral Limited's planned Rs. 600 Cr. capex for its Dahej expansion is structured with a funding mix of ~70% internal accruals (~Rs. 420 Cr.) and ~30% debt (~Rs. 180 Cr.) ^[1].

The incremental debt requirement of ~Rs. 180 Cr. is minimal relative to the company's operating cash generation and will have a negligible impact on leverage. With Epigral reported at a Net Debt-to-EBITDA ratio of 0.8x as of Q1 FY27 ^[2], expected annual internal cash accruals of Rs. 450–550 Cr. ^[3] easily absorb both the capex outlay and debt service obligations, keeping leverage well below rating agency sensitivity thresholds (2.0x) ^[3].

---

Planned Funding Mix (Rs. 600 Cr. Capex)

The Board of Directors approved an estimated capex of Rs. 600 Cr. to set up a 1,25,000 TPA Epoxy Resin & Formulations plant alongside a Multi-Purpose Plant (MPP) at Dahej, Gujarat, targeted for commissioning in H2 FY28 ^[2].

Management's capital allocation framework for major expansion projects maintains a funding mix split of:

• Internal Accruals (~70%): ~Rs. 420 Cr. derived from internal cash flows ^[1].
• Debt Financing (~30%): ~Rs. 180 Cr. raised via long-term debt facilities ^[1].

---

Current Debt Profile & Leverage Impact Analysis

Reported Financial Position

Impact of Incremental Debt

1. Borrowing Requirement vs. Cash Accrual Generation:

• The incremental debt addition is estimated at ~Rs. 180 Cr. over the construction period ending H2 FY28 ^[2].
• Epigral generates expected annual net cash accruals of Rs. 450–550 Cr. ^[3].
• Annual debt repayment obligations for existing lines stand at Rs. 115–120 Cr. over the next two fiscals ^[3]. Consequently, net cash generation covers both scheduled repayments and the required ~Rs. 420 Cr. equity/internal portion of the capex ^[3].

2. Leverage Ratio Trajectory:

• On a standalone balance sheet basis, adding Rs. 180 Cr. debt to the Q4 FY26 net debt baseline of Rs. 557.97 Cr ^[5] would expand gross net debt to ~Rs. 737.97 Cr before taking cash generation into account.
• Assuming annualized EBITDA expands or holds steady at ~Rs. 600–700 Cr as new CPVC (doubling to 150,000 TPA) and ECH capacity (100,000 TPA) commission in H1 FY27 ^[1], peak Net Debt-to-EBITDA is projected to remain between 0.8x and 1.2x.
• CRISIL maintains a CRISIL AA/Stable rating on Epigral ^[3]. CRISIL's negative rating sensitivity threshold triggers only if Net Debt-to-EBITDA exceeds 2.0x on a sustained basis ^[3]. Epigral’s leverage trajectory remains comfortably below this threshold.

---

Key Analytical Considerations & Execution Risks

• Phased Outlay: The Rs. 600 Cr. expenditure is spread across FY27 and FY28 rather than drawn as a single tranche, preventing short-term spikes in financial leverage ^[2].
• Operating Cash Cushion: Epigral's fund-based working capital limits (~Rs. 400 Cr.) experienced low utilization (~9% average), providing liquidity buffer during construction ^[3].
• Cyclical Realization Risk: Epigral's cash generation remains sensitive to Electrochemical Unit (ECU) pricing and raw material price volatility ^[3]. A sharp drop in caustic soda realisations during construction would increase reliance on external debt, though high derivative exposure (~70% targeted revenue contribution by FY28) acts as a margin hedge ^[8].

The Rs. 600 Crore capital expenditure announced by Epigral for its Dahej facility includes 1,25,000 TPA (0.125 MTPA) of incremental production capacity dedicated to Epoxy Resin and Formulations ^[2].

Project Capacity and Timeline Details

Analytical Context

While the project encompasses setting up both an Epoxy Resin & Formulations unit and a Multi-Purpose Plant (MPP) at Dahej, Gujarat, the specific incremental volume capacity (1.25 lakh TPA) is officially attributed exclusively to the epoxy segment ^[2]. Both units are targeted to become operational concurrently by H2 FY28, funded through a blend of internal accruals and debt ^[2].

Strategic Alignment with Specialty Mix Target

The Board-approved Rs 600 Crore capital expenditure directly advances Epigral’s stated strategic pivot from a cyclical commodity Chlor-Alkali producer into a higher-value specialty chemicals and derivatives company ^[9].

• Capacity & Product Additions: The capex will fund a 1,25,000 TPA Epoxy Resin & Formulations plant alongside a Multi-Purpose Plant (MPP) at its Dahej, Gujarat facility, targeted for commissioning in H2 FY28 ^[2].
• Revenue Mix Milestones: Specialty chemicals and derivatives contributed ~50–52% of total revenue in FY26 ^[9]. Management targets increasing this specialty share to ~70% of total revenue by FY28 ^[9].
• Forward Integration & Captive Synergy: The new units will consume captive raw materials—primarily Epichlorohydrin (ECH) and Caustic Soda/Chlorine—produced at the same Dahej complex ^[10]. This forward integration increases Epigral’s internal chlorine consumption from ~75% to ~90–95%, directly insulating the business from Chlor-Alkali pricing volatility ^[9].

---

Projected EBITDA Margin & Profitability Comparison

Management has not disclosed a standalone numeric percentage target for the EBITDA margin of the new Epoxy/MPP facilities; however, the strategic design and vertical integration indicate a structural uplift to consolidated earnings quality ^[9].

• Operating Leverage & Integration Advantage: Sourcing over 50% of raw materials by value internally enhances cost control and captures the entire chemical value chain spread within Dahej ^[10].
• Consolidated Financial Impact: Analysts (Systematix) project a ~17% EBITDA CAGR and ~19% Revenue CAGR over FY26–28E as these value-added capacity additions ramp up, supporting earnings stability over cyclical Chlor-Alkali downturns ^[9].

---

Key Execution Risks & Limits

• Commissioning Lag: Earnings and margin contributions from this project will only materialize starting in H2 FY28 ^[2].
• Capital Drag on Near-Term Returns: ROCE moderated from 24% in Q1 FY26 to 16% in Q1 FY27 due to ongoing capital work in progress (CWIP) across CPVC (+75,000 TPA) and ECH (+50,000 TPA) expansions ahead of their H1 FY27 commissioning ^[12].
• Disclosure Limit: Separate facility-level revenue or margin percentage forecasts for the Rs 600 Cr plant are not publicly reported ^[2].